Key Highlights
- Shares climbed 62.59% over the week to close at $6.65, including a 57.96% single-day gain at Friday's close versus the prior close of $4.21.
- The company said the FDA has indicated willingness to accept an amended Biologics license application for deramiocel, its Duchenne muscular dystrophy cell therapy, following a negative advisory committee vote in late July.
- Cantor Fitzgerald upgraded the stock to Overweight from Neutral, raising its price target to $28 from $3.50, while peer-reviewed HOPE-3 trial data published in The Lancet showed deramiocel slowed upper-limb decline by 54% versus placebo.
- Second-quarter net loss widened to $40.7 million, or $0.70 per share, from $25.9 million a year earlier, with no Revenue recognized and cash and marketable securities of $237.9 million as of June 30, 2026.
A Partial Recovery After a Sharp Regulatory Setback
Capricor Therapeutics, Inc. (NASDAQ:CAPR), the San Diego-based clinical-stage biotechnology company developing cell and exosome-based therapies for rare diseases, saw its shares climb 62.59% this week to close at $6.65. The advance follows a dramatic reset in expectations: shares had collapsed roughly 70% in late July after the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee voted 9 to 3 against the company's Biologics License Application for deramiocel, its lead cell therapy candidate for Duchenne muscular dystrophy-associated cardiomyopathy, questioning whether available data demonstrated substantial evidence of effectiveness.
This week's rally traces to a single after-hours announcement Thursday, when Capricor outlined what it described as a clearer regulatory path forward, sending shares up 67% in extended trading before the gains extended further into Friday's session. The stock remains well below its pre-advisory-committee levels in the high teens, underscoring that this week's move represents a partial recovery of confidence rather than a full Reversal of the earlier selloff.
A Clearer Regulatory Path, Reinforced by New Data and an Analyst Upgrade
Capricor said the FDA has indicated it is willing to accept an amended version of the company's application and, upon receipt, to extend the current August 22 PDUFA action date accordingly. CEO Linda Marbán said the company is working with the FDA on a path forward centered on the therapy's demonstrated improvements in upper-limb skeletal muscle function. The company is finalizing the timing of its submission and said Manufacturing remains ready for an initial launch if the therapy is approved, though commercial readiness activities are continuing at a slower pace pending further regulatory clarity, and all pipeline work not related to deramiocel has been placed on hold.
Adding to the momentum, peer-reviewed data from the pivotal HOPE-3 trial was published in The Lancet during the week, showing deramiocel slowed upper-limb decline by 54% relative to placebo, with additional cardiac benefits observed in largely non-ambulatory patients, a result the company said validates its trial design and pre-specified statistical analysis plan. Cantor Fitzgerald responded with a significant upgrade, moving the stock to Overweight from Neutral and raising its price target to $28 from $3.50, just weeks after slashing that same target from $62 following the advisory committee vote. Oppenheimer separately reiterated an Outperform rating, characterizing the roughly 70% pre-advisory-committee decline as an attractive risk-reward setup given what it viewed as favorable framing of the FDA's original advisory committee question.
Weighing a Binary Regulatory Outcome Against a Widening Cash Burn
The core Investment question remains binary and unresolved. Capricor is directly disputing part of the FDA's original briefing analysis, arguing regulators relied on an outdated statistical plan rather than the pre-specified version under which HOPE-3 met its primary endpoint, and the company has taken the unusual step of publicly releasing its own slides to make that case. Whether the FDA ultimately accepts an amended application on the timeline the company anticipates, and whether that amended application succeeds where the original fell short with its advisory committee, remains genuinely uncertain given the panel's decisive 9 to 3 vote against the therapy just weeks earlier.
Financially, the company reported no revenue in the first half of either 2026 or 2025, as it has not yet secured approval to commercialize deramiocel. Second-quarter net loss widened to $40.7 million from $25.9 million a year earlier, wider than Wall Street's expected loss, while cash, equivalents and marketable securities fell to $237.9 million from $318.1 million at the end of 2025. Management said that cash position, combined with moderated commercial spending pending regulatory clarity, should be sufficient to fund operations for at least the next 12 months. Separately, the company withdrew a motion for a preliminary injunction against distribution partner NS Pharma, choosing to pursue a contractual pricing dispute through arbitration instead, an unresolved matter that adds a further layer of complexity to the commercial picture even if regulatory approval is eventually secured.
Conclusion
Capricor Therapeutics' 62.59% weekly advance to $6.65 reflects a partial restoration of confidence after the FDA signaled willingness to accept an amended application for deramiocel, reinforced by peer-reviewed trial data and a major analyst upgrade, though shares remain far below levels seen before the advisory committee's negative vote. With a binary regulatory decision still pending and no revenue yet on the books, the coming weeks around the amended submission and any updated PDUFA timeline will likely determine whether this rally marks a genuine turning point or another swing in what has become a volatile, event-driven stock.






Please wait processing your request...